Cartesian Therapeutics (RNAC) Short term Debt (2016 - 2023)

Cartesian Therapeutics (RNAC) has 8 years of Short term Debt data on file, last reported at $28.3 million in Q4 2023.

• Short term Debt for Q4 2023 came in at $28.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $28.3 million (changed N/A YoY), and the FY2023 annual result was $28.3 million, changed N/A from the prior year.
• Short term Debt improved to $28.3 million in Q4 2023 per RNAC's latest filing, from $10.2 million in the prior quarter.
• Over five years, Short term Debt peaked at $28.3 million in Q4 2023 and troughed at $460000.0 in Q1 2021.
• A 5-year average of $11.2 million and a median of $9.3 million in 2020 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2021 and 2023: Short term Debt plunged 97.27% in 2021, then soared 1368.1% in 2023.
• A 5-year view of Short term Debt shows it stood at $18.9 million in 2019, then sank by 55.65% to $8.4 million in 2020, then retreated by 28.9% to $6.0 million in 2021, then decreased by 1.38% to $5.9 million in 2022, then jumped by 381.49% to $28.3 million in 2023.
• Business Quant data shows RNAC's Short term Debt at $28.3 million in Q4 2023, $10.2 million in Q2 2023, and $10.2 million in Q1 2023.